Description
Lagging FDA approvals led to a brief absence of Rx to OTC switches in the pharmaceutical marketplace, but 2006 and 2007 saw a number of switches, and Kalorama Information believes this product management tactic will continue to be aggressively utilized as companies seek ways to extend revenue life.
Kalorama Information’s The Return of the Rx to OTC Switch: Market Analysis and Product Management Strategies contians a complete overview of the US market for prescription drugs likely to switch in the following drug categories:
- Allergy and Cold
- Antilipidemic Agents
- Fungal Infections
- Gastrointestinal Drugs
- Hair Loss Treatments
- Migraine Therapy
- Nonsteroidal Anti-inflammatories
- Oral Contraceptives
- Osteoporosis and Hormone Replacement Therapies
- Overactive Bladder
- Sexual Dysfunction
- Sleep Agents
- Smoking Cessation
- Viral Infections
- Others
Kalorama Information believes this trend of utilizing Rx to OTC will continue. There are currently 14 prescription drugs, with worldwide prescription sales exceeding $20 billion in 2006, with the potential to reach the OTC market by the year 2013.
What are the most viable products that are candidates for Rx to OTC switches? Who are the players in the industry best suited to execute this strategy? What is the market potential for Rx to OTC in key categories? And what are the advantages and pitfalls of using this tactic in the current market? These questions and more are answered in this Kalorama Information report, the result of Moutaintop Medical’s exhaustive analysis and interviews with experts in the industry.
License Note: Kalorama Information’s listed default price on its information products reflects a single user license only. Purchasing a global site license (entire company) permits multiple individuals in the company to benefit from this resource.
Table of Contents
TABLE OF CONTENTS
CHAPTER ONE: EXECUTIVE SUMMARY
- Scope of the Report
- Methodology
- Issues and Trends
CHAPTER TWO: RX-TO-OTC PRODUCT AND MARKET ANALYSIS
- Introduction
- Allergy and Cold
- Antilipidemic Agents
- Fungal Infections
- Gastrointestinal
- Hair Loss
- Migraine Therapy
- NSAIDs
- Oral Contraceptives
- Osteoporosis and Hormone Replacement Therapy
- Overactive Bladder
- Sexual Dysfunction
- Sleep Agents
- Ambien
- Lunesta
- Provigil
- Market Analysis
- Smoking Cessation
- Nicotrol Inhalation and Nasal Spray
- Zyban
- Market Analysis
- Viral Infections
- Tamiflu
- Valtrex
- Market Analysis
- Others
CHAPTER THREE: ISSUES AND TRENDS AFFECTING THE RX-TO-OTC SWITCH INDUSTRY
- Proposed Legislation
- Consumers and Rx-to-OTC Switches
- Direct-to-Consumer (DTC) Advertising
- Patient Safety
- FDA Again Considering Third Class of Medicines
- Insurance Reimbursement Issues
- OTC Switch Criteria and FDA Involvement
- Competition Strategies
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Figure 1: Major Markets for Rx to OTC 2008 and 2010
- Figure 2: Number of New Rx-to-OTC Switches per Year 1976-2007
CHAPTER TWO: RX-TO-OTC PRODUCT AND MARKET ANALYSIS
- Figure 3: Revenue, Major Rx to OTC Categories, 2008
- Table 1: Potential Rx-to-OTC Switches, 2008-2013
- Table 2: Rx-to-OTC Market Analysis: Allergy and Cold Treatments
- Table 3: Rx-to-OTC Market Analysis: Antilipidemic Agents
- Table 4: Rx-to-OTC Market Analysis: Fungal Infection Treatments
- Table 5: Rx-to-OTC Market Analysis: Gastrointestinal Treatments
- Table 6: Rx-to-OTC Market Analysis: Hair Loss Treatments
- Table 7: Rx-to-OTC Market Analysis: Migraine Therapies
- Table 8: Rx-to-OTC Market Analysis: NSAIDs
- Table 9: Rx-to-OTC Market Analysis: Oral Contraceptives
- Table 10: Rx-to-OTC Market Analysis: Sleep Agents
- Table 11: Rx-to-OTC Market Analysis: Smoking Cessation
CHAPTER THREE: ISSUES AND TRENDS AFFECTING THE RX-TO-OTC SWITCH INDUSTRY
- Table 12 Leading Rx-to-OTC Switches 1994-2007
- Figure 1: Number of New Rx-to-OTC Switches per Year 1976-2007
- Table 13: Health Insurance Trends in the United States 2003-2006
